Quantitative proteomic analysis of Isorhamnetin treatment in human liver cancer cells | Zendy

Fei Runhuan | Zendy; Haiyan Wei | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Quantitative proteomic analysis of Isorhamnetin treatment in human liver cancer cells

Author(s) -

Fei Runhuan,

Haiyan Wei

Publication year - 2018

Publication title -

journal of medicinal plants research

Language(s) - English

Resource type - Journals

ISSN - 1996-0875

DOI - 10.5897/jmpr2018.6561

Subject(s) - stable isotope labeling by amino acids in cell culture , isorhamnetin , cancer cell , chemistry , cell growth , apoptosis , liver cancer , cell , cell culture , amino acid , biochemistry , proteomics , cancer , cancer research , biology , microbiology and biotechnology , gene , kaempferol , antioxidant , quercetin , genetics

Isorhamnetin (Iso) exhibits antitumor effects in promyelotic leukemia and lung cancers. However, its effect in liver cancer is not clear. This study explored the effects of Iso in human liver cancer cells and profiled the differential proteins upon Iso treatment, which contributes to a better understanding of its anticancer mechanisms. Stable isotope labeling with amino acids in cell culture-mass spectrometry: ESI-Iontrap (SILAC-MS) was used to study the differentially proteomic profile of Iso-treated HepG2 cells. Iso inhibits HepG2 cell proliferation in a dose-dependent manner. A total of 84 proteins are identified, among which 7 proteins were up-regulated while 77 proteins were down-regulated. Iso inhibits HepG2 cell proliferation by the induction of apoptosis and the inhibition of protein synthesis of human liver cancer cell. Key words: Isorhamnetin, Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC), differential proteomic profile, HepG2 cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research